These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 3217425)

  • 1. Therapy of autoimmune disease with monoclonal antibodies to class II gene products of the major histocompatibility complex.
    Steinman L
    Prog Allergy; 1988; 45():161-7. PubMed ID: 3217425
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-class II antibody treatment in autoimmune diseases.
    Boitard C
    Immunol Ser; 1993; 59():279-93. PubMed ID: 8461393
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of autoimmune diseases with antibodies to class II major histocompatibility complex antigens.
    Vladutiu AO
    Clin Immunol Immunopathol; 1991 Oct; 61(1):1-17. PubMed ID: 1959236
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical application of monoclonal antibodies].
    Yata J
    Ryumachi; 1984 Aug; 24(4):288-94. PubMed ID: 6393366
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapy of autoimmune diseases with antibody to immune response gene products or to T-cell surface markers.
    Steinman L; Waldor MK; Zamvil SS; Lim M; Herzenberg L; Herzenberg L; McDevitt HO; Mitchell D; Sriram S
    Ann N Y Acad Sci; 1986; 475():274-84. PubMed ID: 3098154
    [No Abstract]   [Full Text] [Related]  

  • 6. A role for major histocompatibility complex-binding peptides in the immunotherapy of autoimmune disease.
    Wraith DC; Smilek DE
    Springer Semin Immunopathol; 1992; 14(1):95-101. PubMed ID: 1440200
    [No Abstract]   [Full Text] [Related]  

  • 7. In vivo prevention of thyroid and pancreatic autoimmunity in the BB rat by antibody to class II major histocompatibility complex gene products.
    Boitard C; Michie S; Serrurier P; Butcher GW; Larkins AP; McDevitt HO
    Proc Natl Acad Sci U S A; 1985 Oct; 82(19):6627-31. PubMed ID: 3901005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of antigen-specific therapies for autoimmune disease.
    Steinman L
    Mol Biol Med; 1990 Aug; 7(4):333-9. PubMed ID: 2233245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of class II major histocompatibility complex antigens in autoimmune diabetes: animal models.
    Timsit J; Savino W; Boitard C; Bach JF
    J Autoimmun; 1989 Jun; 2 Suppl():115-29. PubMed ID: 2789059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal anti-Ia antibody therapy in animal models of autoimmune disease.
    McDevitt HO; Perry R; Steinman LA
    Ciba Found Symp; 1987; 129():184-93. PubMed ID: 3315501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of EAE in rhesus monkeys with MHC class II specific monoclonal antibodies.
    Jonker M; van Lambalgen R; Mitchell DJ; Durham SK; Steinman L
    J Autoimmun; 1988 Oct; 1(5):399-414. PubMed ID: 3254183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex.
    Aharoni R; Teitelbaum D; Arnon R; Puri J
    Nature; 1991 May; 351(6322):147-50. PubMed ID: 1709449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic strategies using monoclonal antibodies in autoimmune disease.
    Pankewycz O; Strom TB; Kelley VE
    Curr Opin Immunol; 1989 Apr; 1(4):757-63. PubMed ID: 2508704
    [No Abstract]   [Full Text] [Related]  

  • 14. [1990 Apollinaire Bouchardat Prize. Immunology of insulin-dependent diabetes mellitus: in vitro and in vivo study models in animals].
    Boitard C
    Journ Annu Diabetol Hotel Dieu; 1990; ():285-99. PubMed ID: 2195212
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of monoclonal antibodies for treatment of autoimmune disease.
    Steinman L
    J Clin Immunol; 1990 Nov; 10(6 Suppl):30S-38S; discussion 38S-39S. PubMed ID: 2081787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localization and characterization of major histocompatibility complex class II-positive cells in the posterior segment of the eye: implications for induction of autoimmune uveoretinitis.
    Forrester JV; McMenamin PG; Holthouse I; Lumsden L; Liversidge J
    Invest Ophthalmol Vis Sci; 1994 Jan; 35(1):64-77. PubMed ID: 8300365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressing autoimmunity in mice.
    Marx JL
    Science; 1983 Aug; 221(4613):843-5. PubMed ID: 6576470
    [No Abstract]   [Full Text] [Related]  

  • 18. MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases.
    Xu M; Li J; Gulfo JV; Von Hofe E; Humphreys RE
    Scand J Immunol; 2001; 54(1-2):39-44. PubMed ID: 11439146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of rheumatoid arthritis by antibodies directed against class II MHC antigens.
    Sany J
    Scand J Rheumatol Suppl; 1988; 76():289-95. PubMed ID: 3075084
    [No Abstract]   [Full Text] [Related]  

  • 20. Antigen recognition and peptide-mediated immunotherapy in autoimmune disease.
    Smilek DE; Lock CB; McDevitt HO
    Immunol Rev; 1990 Dec; 118():37-71. PubMed ID: 1706681
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.